CIN2 Clinical Trials

7 recruiting

CIN2 Trials at a Glance

8 actively recruiting trials for cin2 are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Mianyang, Liuzhou, and Prague. Lead sponsors running cin2 studies include Shanghai Bovax Biotechnology Co., Ltd., General University Hospital, Prague, and UNC Lineberger Comprehensive Cancer Center.

Browse cin2 trials by phase

Treatments under study

About CIN2 Clinical Trials

Looking for clinical trials for CIN2? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CIN2 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CIN2 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Not Applicable

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Human Papillomavirus InfectionCervical Cancer Screening MethodsCervical Intraepithelial Neoplasia Grade 2 (CIN2)
University Hospital, Geneva1,800 enrolled2 locationsNCT07550010
Recruiting

Regression of Cervical Precancerous Lesions and Associated Risk Factors

HPVCIN2CIN3+1 more
General University Hospital, Prague300 enrolled1 locationNCT06147388
Recruiting

Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

Cervical CancerCIN2High Grade Sil
University of Pretoria1,500 enrolled1 locationNCT02956031
Recruiting
Not Applicable

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

Cervical CancerCIN2CIN3
UNC Lineberger Comprehensive Cancer Center300 enrolled1 locationNCT05413798
Recruiting
Phase 3

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical CancerVaginal CancerVulvar Cancer+11 more
Shanghai Bovax Biotechnology Co., Ltd.8,000 enrolled1 locationNCT04422366
Recruiting

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Vaginal CancerCIN1CIN2+4 more
Shanghai Bovax Biotechnology Co., Ltd.600 enrolled2 locationsNCT05371353
Recruiting
Phase 3

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Vaginal CancerCIN1CIN2+4 more
Shanghai Bovax Biotechnology Co., Ltd.1,348 enrolled1 locationNCT05027776
Recruiting
Phase 3

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Cervical CancerVaginal CancerVulvar Cancer+12 more
Shanghai Bovax Biotechnology Co., Ltd.1,200 enrolled1 locationNCT04895020